Acacia Research Corp. (ACTG) Drops 20.07% on December 21

Equities Staff |

Acacia Research Corp. (ACTG) was one of the Russell 2000's biggest losers for Monday December 21 as the stock slid 20.07% to $4.42, a loss of $-1.11 per share. Starting at an opening price of $5.50 a share, the stock traded between $4.12 and $5.60 over the course of the trading day. Volume was 3.26 million shares over 11,502 trades, against an average daily volume of 590,300 shares and a total float of 50.74 million.

The losses send Acacia Research Corp. down to a market cap of $224.25 million. In the last year, Acacia Research Corp. has traded between $18.88 and $4.12, and its 50-day SMA is currently $6.64 and 200-day SMA is $8.77.

Acacia Research Corporation is an intermediary in the patent marketplace, facilitating efficiency and delivering monetary rewards to patent owners.

Acacia Research Corp. is based out of Newport Beach, CA and has some 57 employees. Its CEO is Matthew Vella.

For a complete fundamental analysis analysis of Acacia Research Corp., check out’s Stock Valuation Analysis report for ACTG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…